<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387448</url>
  </required_header>
  <id_info>
    <org_study_id>GFB-887-201</org_study_id>
    <nct_id>NCT04387448</nct_id>
  </id_info>
  <brief_title>A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease</brief_title>
  <official_title>A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldfinch Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goldfinch Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses
      of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis
      (FSGS), and treatment-resistant minimal change disease (TR-MCD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 125 patients will be enrolled in this study across the United States. Patients
      with DN and FSGS/TR-MCD will be randomized in 3 ascending dose cohorts to receive either
      GFB-887 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multiple-ascending, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in Urine Protein-to-Creatinine Ratio (UPCR)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage change in Urine Albumin-to-Creatinine Ratio (UACR)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of FSGS/TR-MCD patients achieving a modified partial remission</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of FSGS/TR-MCD patients achieving a complete remission</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in 24-hour urine protein excretion</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in 24-hour urine albumin excretion</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients (DN or FSGS/TR-MCD) with a UACR/UPCR decrease of at least 30% of baseline</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients (DN or FSGS/TR-MCD) with a UACR/UPCR decrease of at least 40% of baseline</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients (DN or FSGS/TR-MCD) with a UACR/UPCR decrease of at least 50% of baseline</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in 12-lead electrocardiogram (ECG) parameters, vital signs measurements, and physical examinations</measure>
    <time_frame>Approximately 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in laboratory parameters</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) parameters: maximum observed plasma concentration (Cmax)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters: time of the observed plasma concentration (Tmax)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters: area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Diabetic Nephropathies</condition>
  <condition>Glomerulosclerosis, Focal Segmental</condition>
  <condition>Nephrosis, Lipoid</condition>
  <condition>Urologic Diseases</condition>
  <condition>Diabetes Complications</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Glomerulonephritis</condition>
  <condition>Nephritis</condition>
  <condition>Nephrosis</condition>
  <arm_group>
    <arm_group_label>GFB-887 multiple ascending dose (MAD) active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GFB-887 active once-daily dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFB-887 MAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GFB-887 placebo once-daily dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFB-887</intervention_name>
    <description>Investigational Medicinal Product (IMP)</description>
    <arm_group_label>GFB-887 multiple ascending dose (MAD) active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching</description>
    <arm_group_label>GFB-887 MAD placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients:

               1. Male or female 18-75 years of age, of any race, at the time of signing informed
                  consent.

               2. Estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2 at Screening.

               3. Currently receiving an angiotensin-converting enzyme (ACE) inhibitor or
                  angiotensin receptor blocker (ARB).

          -  For DN patients:

               1. Diagnosis of type 2 diabetes with glycated hemoglobin (HbA1c) level ≤10% at
                  Screening.

               2. UACR ≥ 150 mg/g.

          -  For FSGS/TR-MCD patients:

               1. Diagnosis of FSGS based on either biopsy or genetic testing or TR-MCD based on
                  biopsy.

               2. UPCR ≥ 1.0 g/g.

        Exclusion Criteria:

          -  All patients:

               1. Evidence of another (non-DN, non-FSGS/TR-MCD, respectively) kidney disease.

               2. Body mass index (BMI) &gt;40 kg/m2.

               3. History of malignancy, unless in remission for at least 5 years other than
                  adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in
                  situ, or prostate cancer not expected to require treatment over the course of the
                  study.

               4. History of any organ or bone marrow transplant, including kidney grafts.

               5. History of alcoholism or drug/chemical abuse within 12 months prior to Screening.

          -  For DN patients:

             1. Renal disease that requires immunosuppressive therapy (currently, or in the past).

          -  For FSGS/TR-MCD patients:

               1. Currently on calcineurin inhibitors or history of resistance to calcineurin
                  inhibitors.

               2. Known history of severe or chronic hepatobiliary disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Goldfinch Bio Clinical Trials Information</last_name>
    <phone>(617) 337-4000</phone>
    <email>clinicaltrials@goldfinchbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aventiv Research - Phoenix</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210-6041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Vasquez</last_name>
      <phone>480-588-7752</phone>
      <email>pvasquez@aventivresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Mojave Sage Dialysis</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395-8322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Falcon</last_name>
      <phone>951-565-6284</phone>
      <email>casey.falcon@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Nephrology Associates Research Center, LLC</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Jackman</last_name>
      <phone>941-258-3556</phone>
      <email>bjack302@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masters of Clinical Research</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Gutierrez</last_name>
      <phone>706-210-8890</phone>
      <email>bgutierrez@mcr.net.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhavya Kothapalli</last_name>
      <phone>816-756-1222</phone>
      <email>bhavya@crckcmo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arlington Nephrology, PC</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyna Gomez</last_name>
      <phone>817-557-0168</phone>
      <email>rgomez@arlingtonnephrology.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prolato Clinical Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romeo Parada</last_name>
      <phone>832-338-9118</phone>
      <email>rparada@prolatoresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Texas Kidney Disease Association</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75057-6039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Ellis</last_name>
      <phone>469-307-1880</phone>
      <email>adam.ellis@davita.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

